Structure-guided design of apramycin analogs to overcome resistance and boost effectiveness
Official title: Structure-guided design of apramycin analogs to avoid resistance and enhance efficacy
Funded at Beth Israel Deaconess Medical Center · NIH-11454882 · Data updated 2026-11-12
A study to create and test new apramycin-like molecules aimed at treating hard-to-kill bacteria such as Acinetobacter baumannii and other gram-negative pathogens.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 17, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $844,925 |
| NIH project number | 1R01AI195600-01A1 |
| Project ID | NIH-11454882 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be patients with infections caused by drug-resistant Acinetobacter baumannii or closely related gram-negative bacteria in future clinical contexts.
✕Less likely to help
Patients with infections caused by non-resistant bacteria or infections unlikely to respond to apramycin analogs may not benefit.
What this research studies
Researchers will design apramycin derivatives guided by structure to stay active against resistant bacteria. They will evaluate how changes affect binding, resistance evasion, and potency, and will test versions in lab systems that mimic human infections. The work aims to identify promising compounds for further development as safer, more effective antibiotics. This is focused on addressing serious infections that are difficult to treat with current drugs.
Why it matters
Potential benefit: Potential to yield new antibiotic options for patients with difficult gram-negative infections.
How similar studies have gone: Previous work shows that modifying aminoglycoside structures can overcome resistance while retaining activity, but clinical translation remains ongoing.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Kirby, James E — Beth Israel Deaconess Medical Center
- Study coordinator: Kirby, James E
Related research
Other NIH-funded projects on the same topics.
-
SATURN MRI ancillary study: statins after intracerebral hemorrhage and brain MRI markers
This study looks at what happens to brain MRI markers and health outcomes when people with a specific type of brain bleed continue or stop taking statins.
-
Statin use after brain bleed MRI study in ICH patients (SATURN MRI) Ancillary Study
This project tests whether continuing or stopping statin therapy after an intracerebral hemorrhage affects brain changes seen on MRI and related health outcomes in people with lobar ICH.
-
Statin use after brain bleed: SATURN MRI ancillary study
This project tests whether continuing statin medicines after a brain bleed (lobar intracerebral hemorrhage) affects new brain blood vessel findings and long-term health.
-
XenCAT: Single Cell Atlas for Xenopus
Aims to map gene activity at the single-cell level in Xenopus to help understand how cells develop and how this relates to human disease.
-
Statin use after lobar intracerebral hemorrhage
This trial compares continuing versus stopping statins in people who had a lobar intracerebral hemorrhage to see how that affects repeat brain bleeds, strokes, heart attacks, and recovery over two years.
-
Statin use after lobar brain hemorrhage
This trial compares stopping versus continuing statin medicine in people who had a lobar brain bleed to learn effects on repeat bleeding and future heart or stroke events.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.